keyword
MENU ▼
Read by QxMD icon Read
search

Cipn

keyword
https://www.readbyqxmd.com/read/28635977/chemotherapy-induced-peripheral-neuropathy-assessment-tools-a-systematic-review
#1
Haryani Haryani, Susan Jane Fetzer, Ching-Lin Wu, Yu-Yun Hsu
PROBLEM IDENTIFICATION: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting chemotherapy toxicity, which has a long-lasting effect and decreases quality of life. Although several tools have been developed to detect CIPN, the study quality, psychometric properties, and practicality of CIPN assessment tools have not been systematically reviewed.
. LITERATURE SEARCH: Electronic searches using keywords were conducted in Medline, PubMed, CINAHL®, and Cochrane Library for articles published from 1980-2015...
May 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28634676/evaluation-of-the-psychometric-properties-of-the-eortc-chemotherapy-induced-peripheral-neuropathy-questionnaire-qlq-cipn20
#2
Jacobien M Kieffer, Tjeerd J Postma, Lonneke van de Poll-Franse, Floortje Mols, Jan J Heimans, Guido Cavaletti, Neil K Aaronson
PURPOSE: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). METHODS: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors...
June 20, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28634656/patient-reported-eortc-qlq-cipn20-versus-physician-reported-ctcae-quantification-of-oxaliplatin-and-paclitaxel-carboplatin-induced-peripheral-neuropathy-in-ncctg-alliance-clinical-trials
#3
Jennifer Le-Rademacher, Rahul Kanwar, Drew Seisler, Deirdre R Pachman, Rui Qin, Alexej Abyzov, Kathryn J Ruddy, Michaela S Banck, Ellen M Lavoie Smith, Susan G Dorsey, Neil K Aaronson, Jeff Sloan, Charles L Loprinzi, Andreas S Beutler
PURPOSE: Clinical practice guidelines on chemotherapy-induced peripheral neuropathy (CIPN) use the NCI Common Terminology Criteria for Adverse Events (CTCAE), while recent clinical trials employ a potentially superior measure, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20), a patient-reported outcome (PRO). Practitioners and researchers lack guidance, regarding how QLQ-CIPN20 results relate to the traditional CTCAE during the serial assessment of patients undergoing chemotherapy...
June 20, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28620884/kinetic-pharmacodynamic-model-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-metastatic-breast-cancer-treated-with-paclitaxel-nab-paclitaxel-or-ixabepilone-calgb-40502-alliance
#4
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, Kehua Wu, William T Barry, Clifford Hudis, Eric P Winer, Alan P Lyss, Deborah L Toppmeyer, Alvaro Moreno-Aspitia, Thomas E Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J Ratain, Jogarao V Gobburu
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity caused by several chemotherapeutic agents. Currently, CIPN is managed by empirical dose modifications at the discretion of the treating physician. The goal of this research is to quantitate the dose-CIPN relationship to inform the optimal strategies for dose modification. Data were obtained from the Cancer and Leukemia Group B (CALGB) 40502 trial, a randomized phase III trial of paclitaxel vs. nab-paclitaxel vs. ixabepilone as first-line chemotherapy for locally recurrent or metastatic breast cancer...
June 15, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28600844/pain-in-chemotherapy-induced-peripheral-neurotoxicity
#5
REVIEW
Paola Marmiroli, Arianna Scuteri, David R Cornblath, Guido Cavaletti
Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) is a potentially dose-limiting side effect of the treatment of several cancers. CIPN is predominantly or exclusively sensory, and it is frequently associated with unpleasant symptoms, overall referred to as "pain". However, given the markedly different clinical presentation and course of CIPN depending on the antineoplastic drug used, the broad term "pain" in the specific context of CIPN needs to be reconsidered and refined. In fact, a precise identification of the features of CIPN has relevant implication in the design of rational-based clinical trials and in the selection of possible active drugs...
June 10, 2017: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/28589310/optimal-clinical-assessment-strategies-for-chemotherapy-induced-peripheral-neuropathy-cipn-a-systematic-review-and-delphi-survey
#6
J Matt McCrary, David Goldstein, Frances Boyle, Keith Cox, Peter Grimison, Matthew C Kiernan, Arun V Krishnan, Craig R Lewis, Kate Webber, Sally Baron-Hay, Lisa Horvath, Susanna B Park
BACKGROUND/PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use. METHODS: Relevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane...
June 7, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28587059/selected-risk-nutritional-factors-for-chemotherapy-induced-polyneuropathy
#7
Jiri Grim, Alena Ticha, Radomir Hyspler, Martin Valis, Zdenek Zadak
The present study seeks to identify the nutritional risk factors involved in the development of neuropathies induced by chemotherapeutic treatments. Unlike the gastrointestinal or hematological adverse effects of chemotherapy there is no protective treatment strategy for polyneuropathy. The aim of this study was to find possible deficiencies in nutritional factors, which can be used for supplementation in the future for prevention of chemotherapy-induced neuropathy development. We analyzed 70 patients undergoing paclitaxel chemotherapy and evaluated the risk factors involved in chemotherapy-induced peripheral neuropathy (CIPN)...
May 25, 2017: Nutrients
https://www.readbyqxmd.com/read/28586243/falls-functioning-and-disability-among-women-with-persistent-symptoms-of-chemotherapy-induced-peripheral-neuropathy
#8
Kerri M Winters-Stone, Fay Horak, Peter G Jacobs, Phoebe Trubowitz, Nathan F Dieckmann, Sydnee Stoyles, Sara Faithfull
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may persist after treatment ends and may lead to functional decline and falls. This study compared objective and self-report measures of physical function, gait patterns, and falls between women cancer survivors with and without symptoms of CIPN to identify targets for functional rehabilitation. Methods A secondary data analysis of 512 women cancer survivors (age, 62 ± 6 years; time since diagnosis, 5.8 ± 4.1 years) categorized and compared women self-reporting symptoms of CIPN (CIPN+) with asymptomatic women (CIPN-) on the following: maximal leg strength, timed chair stand, physical function battery, gait characteristics (speed; step number, rate, and length; base of support), self-report physical function and disability, and falls in the past year...
June 6, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28577231/electronic-versus-paper-pencil-methods-for-assessing-chemotherapy-induced-peripheral-neuropathy
#9
Robert Knoerl, Evan Gray, Carrie Stricker, Sandra A Mitchell, Kelsey Kippe, Gloria Smith, William N Dudley, Ellen M Lavoie Smith
PURPOSE: The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0-10 Neuropathy Screening Question (NSQ)...
June 2, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28551844/a-pilot-study-of-minocycline-for-the-prevention-of-paclitaxel-associated-neuropathy-accru-study-ru221408i
#10
Deirdre R Pachman, Travis Dockter, Patricia J Zekan, Briant Fruth, Kathryn J Ruddy, Lauren E Ta, Jacqueline M Lafky, Todor Dentchev, Nguyet Anh Le-Lindqwister, William M Sikov, Nathan Staff, Andreas S Beutler, Charles L Loprinzi
PURPOSE: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Given that extensive animal data suggest that minocycline may prevent chemotherapy-induced neurotoxicity, the purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and the P-APS. METHODS: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks and were randomized to receive minocycline 200 mg on day 1 followed by 100 mg twice daily or a matching placebo...
May 27, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28548225/single-and-combined-effects-of-delta-9-tetrahydrocannabinol-and-cannabidiol-in-a-mouse-model-of-chemotherapy-induced-neuropathic-pain
#11
Kirsten M King, Alyssa M Myers, Ariele J Soroka-Monzo, Ronald F Tuma, Ronald J Tallarida, Ellen A Walker, Sara Jane Ward
BACKGROUND AND PURPOSE: It has been suggested that the non-psychoactive phytocannabinoid cannabidiol (CBD) can impact the pharmacological effects of delta-9-tetrahydrocannabinol (THC). We tested the hypothesis that CBD and THC would significantly mitigate mechanical sensitivity in a mouse model of paclitaxel-induced neuropathic pain, and that CBD+THC combinations would produce synergistic effects. We also tested the hypothesis that CBD would attenuate oxaliplatin- and vincristine- induced mechanical sensitivity...
May 26, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28533610/effects-of-transcutaneous-electrical-nerve-stimulation-on-chemotherapy-induced-peripheral-neuropathy-symptoms-cipn-a-preliminary-case-control-study
#12
Tania Tonezzer, Leonardo Affonso Massabki Caffaro, Katiuscia Rosette Scasni Menon, Fabíola Cristina Brandini da Silva, Christina May Moran de Brito, Almir José Sarri, Raquel Aparecida Casarotto
[Purpose] The aim of this double-blind, randomized and placebo-controlled study is to investigate the effects of Transcutaneous Electrical Nerve Stimulation for reducing the side effects of Chemotherapy-induced Peripheral Neuropathy in cancer patients undergoing chemotherapy with oxaloplatin or paclitaxel. [Subjects and Methods] Twenty-four patients were randomly allocated into two groups: active or placebo stimulation. All patients were assessed for pain, numbness/tingiling, frequency of symptoms, and quality of life...
April 2017: Journal of Physical Therapy Science
https://www.readbyqxmd.com/read/28511129/neurophysiological-and-clinical-outcomes-in-chemotherapy-induced-neuropathy-in-cancer
#13
REVIEW
Tejaswi Kandula, Michelle A Farrar, Matthew C Kiernan, Arun V Krishnan, David Goldstein, Lisa Horvath, Peter Grimison, Frances Boyle, Sally Baron-Hay, Susanna B Park
Chemotherapy induced peripheral neuropathy (CIPN) is a significant toxicity of cancer treatment, with the potential to affect long-term function and quality of life in cancer survivors. There remains a lack of consensus around optimal assessment techniques. While current approaches to CIPN assessment are focused on clinical grading scales, it is becoming increasingly evident that a more comprehensive multimodal assessment package is necessary to accurately characterise the impact of CIPN as well as gauge the utility of neuroprotective mechanisms...
July 2017: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/28486769/chemotherapy-induced-peripheral-neuropathy-a-current-review
#14
REVIEW
Nathan P Staff, Anna Grisold, Wolfgang Grisold, Anthony J Windebank
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve...
June 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28458631/inhibition-of-mitochondrial-p53-accumulation-by-pft-%C3%AE-prevents-cisplatin-induced-peripheral-neuropathy
#15
Magdalena A Maj, Jiacheng Ma, Karen N Krukowski, Annemieke Kavelaars, Cobi J Heijnen
Chemotherapy-induced peripheral neuropathy (CIPN), a debilitating major side effect of cancer treatment, is characterized by pain and sensory loss in hand and feet. Platinum-based chemotherapeutics like cisplatin frequently induce CIPN. The molecular mechanism underlying these neurotoxic symptoms is incompletely understood and there are no preventive or curative interventions. We hypothesized that cisplatin acts as a cellular stressor that triggers p53 accumulation at mitochondria, leading to mitochondrial dysfunction and CIPN...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/28458593/intravenous-lidocaine-old-school-drug-new-purpose-reduction-of-intractable-pain-in-patients-with-chemotherapy-induced-peripheral-neuropathy
#16
Sandra A S van den Heuvel, Selina E I van der Wal, Lotte A Smedes, Sandra A Radema, Nens van Alfen, Kris C P Vissers, Monique A H Steegers
Background. Treatment of intractable pain due to chemotherapy induced peripheral neuropathy (CIPN) is a challenge. Intravenous (iv) lidocaine has shown to be a treatment option for neuropathic pain of different etiologies. Methods. Lidocaine (1.5 mg/kg in 10 minutes followed by 1.5 mg/kg/h over 5 hours) was administered in nine patients with CIPN, and analgesic effect was evaluated during infusion and after discharge. The immediate effect of lidocaine on pressure pain thresholds (PPT) and the extent of the stocking and glove distribution of sensory abnormalities (cold and pinprick) were assessed...
2017: Pain Research & Management: the Journal of the Canadian Pain Society
https://www.readbyqxmd.com/read/28423567/cxcr1-2-pathways-in-paclitaxel-induced-neuropathic-pain
#17
Laura Brandolini, Elisabetta Benedetti, Pier Adelchi Ruffini, Roberto Russo, Loredana Cristiano, Andrea Antonosante, Michele d'Angelo, Vanessa Castelli, Antonio Giordano, Marcello Allegretti, Annamaria Cimini
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic pain that represents a frequent and serious consequence of chemotherapy agents. Over the last years, significant progress has been achieved in elucidating the underlying pathogenesis of CIPN. The interference of taxanes with microtubule has been proposed as a mechanism that leads to altered axonal transport and to permanent neurological damages. The inflammatory process activated by chemotherapeutic agents has been considered as a potential trigger of nociceptive process in CIPN...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28421360/update-on-chemotherapy-induced-peripheral-neuropathy
#18
REVIEW
Comana Cioroiu, Louis H Weimer
PURPOSE OF REVIEW: The purpose of this study was to briefly discuss chemotherapy-induced peripheral neuropathy (CIPN) and detail the most important and most recent chemotherapeutic agents implicated. This review will examine neuropathy mechanisms, risk factors, and clinical patterns; novel and prospective drugs with similar effects that are less well known to neurologists are discussed. RECENT FINDINGS: CIPN is increasingly recognized for its clinical importance and effect on patient quality of life...
June 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28400846/lifestyle-related-factors-in-the-self-management-of-chemotherapy-induced-peripheral-neuropathy-in-colorectal-cancer-a-systematic-review
#19
REVIEW
Tess M E Derksen, Martijn J L Bours, Floortje Mols, Matty P Weijenberg
Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of chemotherapy treatment in colorectal cancer (CRC), negatively affecting the daily functioning and quality of life of CRC patients. Currently, there are no established treatments to prevent or reduce CIPN. The purpose of this systematic review was to identify lifestyle-related factors that can aid in preventing or reducing CIPN, as such factors may promote self-management options for CRC patients suffering from CIPN. Methods...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28391556/microtubule-targeting-agents-eribulin-and-paclitaxel-differentially-affect-neuronal-cell-bodies-in-chemotherapy-induced-peripheral-neuropathy
#20
Sarah J Benbow, Krystyna M Wozniak, Bridget Kulesh, April Savage, Barbara S Slusher, Bruce A Littlefield, Mary Ann Jordan, Leslie Wilson, Stuart C Feinstein
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment with microtubule-targeted agents (MTAs). The frequency of severe CIPN, which can be dose limiting and even life threatening, varies widely among different MTAs. For example, paclitaxel induces a higher frequency of severe CIPN than does eribulin. Different MTAs also possess distinct mechanisms of microtubule-targeted action. Recently, we demonstrated that paclitaxel and eribulin differentially affect sciatic nerve axons, with paclitaxel inducing more pronounced neurodegenerative effects and eribulin inducing greater microtubule stabilizing biochemical effects...
July 2017: Neurotoxicity Research
keyword
keyword
30770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"